FY2023 · ended Dec 31, 2023 · Revenue $237,000, -60.2% YoY · Filed Mar 2, 2026
Geron Corp (GERN) files with the SEC under industry code 2834, Pharmaceutical Preparations. As of Sep 30, 2026 it held $69.2 million in cash and investments and $121.2 million in total debt.
Revenue
$237,000
-60.2% vs prior year
Net income (TTM)
$-47.83M
+40.2% vs year-ago TTM
Operating cash flow (TTM)
$-90.53M
+31.9% vs year-ago TTM
Free cash flow
$-219.30M
-30.1% vs prior year
EPS (TTM)
$-0.07
+40.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
640.54M
+0.6% vs prior year
Net cash
$-52.05M
as of Sep 30, 2026
Operating margin
-81832.9%
FY 2023
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- GERN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Foster City, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 886744
- Former names
- GERON CORPORATION (until Aug 5, 2005)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | — | — | $237,000 | $596,000 | $1.4M |
| Operating income | -$68.6M | -$173.7M | -$193.9M | -$138.6M | -$114.0M |
| Net income | -$83.5M | -$174.6M | -$184.1M | -$141.9M | -$116.1M |
| Diluted EPS | -$0.13 | -$0.27 | -$0.32 | -$0.37 | — |
| Operating cash flow | -$111.0M | -$218.6M | -$167.7M | -$127.4M | -$95.6M |
| Free cash flow | — | -$219.3M | -$168.6M | -$127.8M | -$95.8M |
| Total assets | $570.5M | $593.8M | $394.1M | $190.6M | $226.0M |
| Total liabilities | $344.7M | $313.5M | $146.1M | $110.6M | $99.6M |
| Stockholders' equity | $225.9M | $280.3M | $247.9M | $80.0M | $126.4M |
| Cash and investments | $77.6M | $501.1M | $377.0M | $172.7M | $212.4M |
| Total debt | $122.0M | $121.7M | $85.9M | $55.8M | $55.0M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 4, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Nov 4, 2026 | Nov 4, 2026 |
| 8-K |
Current report
Other events
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 5, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
May 27, 2026 | May 20, 2026 |
All 1002 Geron Corp SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.